These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26972918)

  • 1. Clotting factor concentrate use and occurrence of thrombotic events in patients with hemophilia: A nationwide and 15-year cohort study.
    Tsan YT; Wang JD; Chan WC; Tong KM
    Am J Hematol; 2016 Jun; 91(6):E307-8. PubMed ID: 26972918
    [No Abstract]   [Full Text] [Related]  

  • 2. Living donor liver transplantation for hemophilia with special reference to the management of perioperative clotting factor replacement.
    Togashi J; Akamatsu N; Tanaka T; Sugawara Y; Tsukada K; Kaneko J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N
    Liver Transpl; 2016 Mar; 22(3):366-70. PubMed ID: 26390184
    [No Abstract]   [Full Text] [Related]  

  • 3. Innovations in coagulation: improved options for treatment of hemophilia A and B.
    Pabinger-Fasching I; Pipe S
    Thromb Res; 2013 Mar; 131 Suppl 2():S1. PubMed ID: 23537720
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.
    Coppola A; Franchini M; Makris M; Santagostino E; Di Minno G; Mannucci PM
    Haemophilia; 2012 May; 18(3):e173-87. PubMed ID: 22335611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, incidence, and factor concentrate usage trends of hemophiliacs in Taiwan.
    Tu TC; Liou WS; Chou TY; Lin TK; Lee CF; Chen JD; Cham TM; Chung MI
    Yonsei Med J; 2013 Jan; 54(1):71-80. PubMed ID: 23225801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of donated clotting factors for surgeries on haemophilic patients in a resource-constrained country: a kind donor, good outcome, change of practice and future directions.
    Poudyal BS; Shrestha GS; Tuladhar S; Gyawali B; Sedain G; Battajo R; Maskey P; Paudyal S; Regmi S; Rc DR; Kouides P
    Haemophilia; 2016 Sep; 22(5):e453-5. PubMed ID: 27353411
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee.
    Kasper CK; Lusher JM
    Transfusion; 1993 May; 33(5):422-34. PubMed ID: 8488548
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin.
    Yamamoto K; Honda T; Matsushita T; Kojima T; Takamatsu J
    J Thromb Haemost; 2006 Feb; 4(2):469-70. PubMed ID: 16420581
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnosis and treatment of congenital hemophilia with inhibitors a Latin American perspective.
    Pérez Bianco R; Ozelo MC; Villaça PR; Solano MH; Jimenez Cruze G; Martinez Murillo C; Garcia Chavez J; Mendoza S; Rodriguez Grecco I; Ruiz-Saez A
    Medicina (B Aires); 2008; 68(3):227-42. PubMed ID: 18689157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemophilia.
    Brody H
    Nature; 2014 Nov; 515(7528):S157. PubMed ID: 25427203
    [No Abstract]   [Full Text] [Related]  

  • 12. Complications with clotting-factors.
    Lancet; 1972 Apr; 1(7753):729-30. PubMed ID: 4111198
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacotherapy of hemophilia with the preparation of Lagochilus inebrians BGE].
    Akopow IE
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1971; 95(1):72-83. PubMed ID: 4104085
    [No Abstract]   [Full Text] [Related]  

  • 14. Haemophilia treatment: where to from here? Have the risks increased?
    Faed J
    N Z Med J; 2003 Aug; 116(1180):U559. PubMed ID: 14581981
    [No Abstract]   [Full Text] [Related]  

  • 15. Half-life extension technologies for haemostatic agents.
    Mannucci PM
    Thromb Haemost; 2015 Jan; 113(1):165-76. PubMed ID: 25274414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate).
    Negrier C; Voisin S; Baghaei F; Numerof R; Novack A; Doralt JE; Romanov V; Gringeri A;
    Blood Coagul Fibrinolysis; 2016 Jul; 27(5):551-6. PubMed ID: 26829366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events.
    Ehrlich HJ; Henzl MJ; Gomperts ED
    Haemophilia; 2002 Mar; 8(2):83-90. PubMed ID: 11952842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Population and molecular-genetic aspects of hemophilia A and B in Uzbekistan].
    Boboev KT
    Tsitol Genet; 2008; 42(2):51-4. PubMed ID: 18630121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to clotting factors among persons with hemophilia A or B.
    Armstrong EP; Malone DC; Krishnan S; Wessler MJ
    Hematology; 2015 Apr; 20(3):148-53. PubMed ID: 25001343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.